A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
Dr Isa Ryan joins Ethics Talk to discuss her article, coauthored with Dr Ashish Premkumar and Professor Katie Watson: “Why the Post-Roe Era Requires Protecting Conscientious Provision as We Protect Conscientious Refusal in Health Care.”
The FDA’s approval for over-the-counter sales of emergency contraception marked a departure from its standard approval process and obstructed access to a safe and effective drug. That departure could set a dangerous precedent for future decisions.